clinical trial · NCT06498986
A Study of BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
Sichuan Baili Pharmaceutical Co., Ltd.·phase2·recruiting·n = 40
Non-small Cell Lung CancerBL-B01D1Osimertinib Mesylate Tablets
brief summary
This phase II clinical study is a study to explore the efficacy and safety of BL-B01D1 in combination with Osimertinib Mesylate Tablets in patients with histologically and/or cytologically confirmed locally advanced or metastatic non-small cell lung cancer.
started
Jul 31, 2024
primary completion
Aug 1, 2026
completion
Aug 1, 2026
last updated
May 7, 2025
official title
A Phase II Clinical Study to Evaluate the Efficacy and Safety of BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol